Back to Results

Twist Bioscience Corp (TWST)

Featured in Overvalued Stocks High-Momentum Stocks

Twist Bioscience Corporation is a biotechnology company listed on the NASDAQ under the ticker TWST. The company develops and sells synthetic DNA-based products, including synthetic genes, gene fragments, oligo pools, immunoglobulin G proteins, and a range of next-generation sequencing tools. Its products are used in therapeutics, diagnostics, chemicals and materials, food and agriculture, data storage, and academic research, with customers spanning biotech and pharmaceutical companies, industrial and agricultural users, and research laboratories. Twist Bioscience also offers methylation detection kits, RNA sequencing workflow solutions, and a variety of synthetic viral controls and research panels for assay development and disease research. In addition, the company provides precision DNA libraries and antibody optimization solutions, and it has a strategic collaboration with bitBiome Inc. Founded in 2013, Twist Bioscience is headquartered in South San Francisco, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-TWST
$57.45
-39.0% Downside
Overvalued
$92.50
-1.8% Downside
Fair
Good
—
—
—
0.0%
August 3, 2026
-72.3x
12.9x
14.4x
5.446 B
5.75 B
2.0%
88.9%
11.8
—
116.9%
Valuation • Fair Value

Twist Bioscience Corp (NASDAQ-TWST) Fair Value by Valuation Model

Compare the primary fair value estimate for Twist Bioscience Corp (NASDAQ-TWST) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$57.45

Estimated downside of 39.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$54.34

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$60.04

Comparable-company valuation reference.

Analyst Price Target

$92.50

Analysts imply downside of 1.8%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Twist Bioscience Corp (NASDAQ-TWST) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Twist Bioscience Corp (NASDAQ-TWST)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

409.5 M

Current operating scale indicator.

Revenue Forecast

446.6 M

Forward revenue estimate.

EBITDA

-109.8 M

Current operating profitability reference.

EBITDA Forecast

-109.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Twist Bioscience Corp (NASDAQ-TWST) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Twist Bioscience Corp (NASDAQ-TWST)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.18

Intermediate zone that deserves monitoring.

Altman Z-Score

11.8

Relatively strong balance-sheet zone.

FCF / Net Income

116.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Twist Bioscience Corp (NASDAQ-TWST). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Twist Bioscience Corp (NASDAQ-TWST)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 3, 2026

Days to Earnings

13

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Twist Bioscience Corp (NASDAQ-TWST), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Twist Bioscience Corp (NASDAQ-TWST) Stock Forecast & Technical Outlook

Review Twist Bioscience Corp (NASDAQ-TWST) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Twist Bioscience Corp (NASDAQ-TWST) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Twist Bioscience Corp (NASDAQ-TWST) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Twist Bioscience Corp (NASDAQ-TWST) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Twist Bioscience Corp (NASDAQ-TWST) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Twist Bioscience Corp (NASDAQ-TWST) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Twist Bioscience Corp (NASDAQ-TWST)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Twist Bioscience Corp (NASDAQ-TWST) has a Strong Buy consensus, with 7 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 7
Hold 2
Sell 0
FAQ • Fast Investor Answers

Twist Bioscience Corp (NASDAQ-TWST) Stock FAQ

Quick answers about Twist Bioscience Corp (NASDAQ-TWST) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$57.45
Estimated downside 39.0%
Valuation Rating
Overvalued
Estimated downside of 39.0%
Analyst Target
$92.50
Implied downside 1.8%
Financial Health
Good
Current financial-health read

The current fair value estimate for Twist Bioscience Corp (NASDAQ-TWST) is $57.45. This implies an estimated downside of 39.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 39.0% versus the current market price.

The available analyst price target for Twist Bioscience Corp (NASDAQ-TWST) is $92.50. The analyst target implies estimated downside of 1.8%.

The current financial health read for Twist Bioscience Corp (NASDAQ-TWST) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Twist Bioscience Corp (NASDAQ-TWST) is August 3, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Twist Bioscience Corp (NASDAQ-TWST) is -72.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Twist Bioscience Corp is 5.446 B.

The current enterprise value listed for Twist Bioscience Corp is 5.75 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Twist Bioscience Corp is NASDAQ-TWST, and the stock is listed on NASDAQ.

Twist Bioscience Corp (NASDAQ-TWST) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Twist Bioscience Corp is 2.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Twist Bioscience Corp is 88.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)